Follicular-phase ovarian follicular fluid and plasma cytokine profiling of natural cycle in vitro fertilization patients

Baskind, N. Ellissa; Orsi, Nicolas M.; Sharma, Vinay

doi:10.1016/j.fertnstert.2014.04.032

Cited by 30 publications

(25 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The composition of FF varies throughout the phases of follicular development (Baskind et al 2014). It is postulated that during the follicular phase, the basement membrane is intact, thereby preventing exchange from the theca cell compartment to the avascular granulosa cell compartment (Duffy et al 2019).…”

Section: Human Ffmentioning

confidence: 99%

“…It is postulated that during the follicular phase, the basement membrane is intact, thereby preventing exchange from the theca cell compartment to the avascular granulosa cell compartment (Duffy et al 2019). When the luteal surge occurs, the basement membrane ruptures, causing vascular changes within the follicle resulting in invasion of capillaries with influx of various cells into the FF (Baskind et al 2014). The phases of follicular development are therefore relevant when reviewing FF composition and function.…”

Section: Human Ffmentioning

confidence: 99%

“…Cytokines are small-molecular-weight glycoproteins that act as intercellular mediators across various immune effector cells, ovarian somatic cells and the oocyte (Vujisic & Zidovec 2005, Baskind et al 2014. The following cytokines have been found in FF: IL1a and IL1B, IL2, IL6, IL8, IL10, IL11, IL12, IL13, IL17A, IL18, IL23, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), TNFa, vascular endothelial growth factor (VEGF), EGF, platelet-derived growth factor (PDGF), IGF, leukemia inhibitory factor (LIF), fibroblast growth factor (FGF), RANTES (CCL5) and stem cell factor (SCF) (Vujisic & Zidovec 2005, Sabbaghi et al 2014.…”

Section: Cytokines In Human Ffmentioning

confidence: 99%

“…In the thecal cell layer of the human ovarian follicle, the presence of IL1B has been described, and an increase of intrafollicular IL1B at the time of ovulation is seen (Brannstrom et al 1994). Furthermore, IL1B induces granulosa cell and theca cell IL6 and IL8 production (Baskind et al 2014). In IVF patients, high levels of IL1B in FF were associated with good fertilization rates (Zollner et al 2013).…”

Section: Cytokines In Human Ffmentioning

confidence: 99%

See 3 more Smart Citations

Is there an immune modulating role for follicular fluid in endometriosis? A narrative review

et al. 2020

View full text Add to dashboard Cite

Follicular fluid (FF) surrounds the granulosa cell–oocyte complex and is one of the mediating factors in the communication between the cells within the follicle. Literature reveals that human FF and its components are key factors to the success of natural fertilization. Among other substances, FF consists of multiple cytokines and immune cells, including interleukin 6 (IL6), IL12, sHLA-G, macrophages, NK cells and lymphocytes. Together, these cells and cytokines might influence the oocyte–granulosa–cell complex. Altered balances of immune content might be involved in changes on folliculogenesis, oocyte maturation, oocyte quality and ovulation. Furthermore, these altered balances are possibly involved in infertility associated with immune-mediated diseases such as endometriosis. The aim of this narrative review is to elaborate on the function and contents of FF and its immunological profile in patients with endometriosis. A comprehensive literature search was performed for the published literature on FF (immune) contents, FF function and FF content alterations in endometriosis patients. In FF of patients with endometriosis, elevated levels of macrophages and several cytokines have been reported. The role of specific immune cells in FF and a clarification of the biological mechanism in healthy women and endometriosis patients remain largely unknown. Future studies in this field will give us more insight in the role of FF immune cells and the effect of altered balances in patients with endometriosis.

show abstract

Section: Human Ffmentioning

confidence: 99%

Section: Human Ffmentioning

confidence: 99%

Section: Cytokines In Human Ffmentioning

confidence: 99%

Section: Cytokines In Human Ffmentioning

confidence: 99%

See 2 more Smart Citations

Is there an immune modulating role for follicular fluid in endometriosis? A narrative review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cytokines will be profiled in plasma and endotracheal tube secretions by multiplex immunoassay (Bio-Plex Pro™; Bio-Rad, Laboratories, Inc., Hercules, CA, USA) on a Luminex ® 200™ System (Luminex Corporation, Austin, TX, USA) cytometer equipped with Bio-Plex Manager software (version 6.11; Bio-Rad, Laboratories, Inc.). 28 The following multiplex immunoassay kits will be used: Plasma samples will be diluted in accordance with the manufacturer's recommendations. For the endotracheal tube secretions, a small aliquot (i.e.…”

Section: Cytokine Profilingmentioning

confidence: 99%

Very low-dose dexamethasone to facilitate extubation of preterm babies at risk of bronchopulmonary dysplasia: the MINIDEX feasibility RCT

et al. 2019

View full text Add to dashboard Cite

Background Postnatal corticosteroids are used to improve lung function and reduce the incidence of bronchopulmonary dysplasia (BPD) in preterm babies. However, corticosteroids may be associated with adverse neurodevelopment. Despite a lack of evidence, some clinicians in the UK use very low-dose regimens of dexamethasone hoping for positive pulmonary effects and optimal neurodevelopment. Objectives To assess the efficacy and safety of very low-dose dexamethasone at facilitating the extubation of ventilator-dependent preterm babies born at < 30 weeks’ gestation and who are at high risk of developing BPD. Design A multicentre, randomised, masked, parallel-group, placebo-controlled Phase 2b trial. The trial was designed as a feasibility study for a subsequent trial of clinical effectiveness. Setting The study was set in 11 tertiary neonatal units in the UK. Participants Ventilator-dependent preterm babies born at < 30 weeks’ gestation aged 10–21 days, receiving at least 30% inspired oxygen and at high risk of developing BPD. Exclusions were babies who had received previous courses of postnatal steroids for respiratory disease; had a severe congenital anomaly affecting the lungs, heart or central nervous system, or had a surgical abdominal procedure or patent ductus arteriosus ligation; and had an illness or medication for which postnatal corticosteroid would be contraindicated (e.g. confirmed or suspected acute sepsis, acute necrotising enterocolitis/focal intestinal perforation or cyclo-oxygenase therapy). Interventions Babies were randomised to very low-dose dexamethasone (50 µg/kg/day for 13 doses) or a matched placebo. Samples of blood and bronchoalveolar lavage fluid from a subset of babies randomised at three participating sites were sent for cytokine analysis at randomisation and at days 5, 7, 10 and 14 of treatment. Primary outcome Time to extubation. Secondary outcomes Secondary outcomes included rates of extubation by day 7 of the intervention; survival to 36 weeks’ postmenstrual age (PMA) or discharge home; respiratory morbidity to 36 weeks’ PMA or discharge home; cytokine profile; safety outcomes; and parent/family experience. Results The main metric of feasibility, namely recruitment, proved difficult. There was a tendency for open-label medication and a higher than predicted rate of suspected/confirmed sepsis among babies. Recruitment was halted after 22 babies had been enrolled. It was found that, compared with the placebo group, a higher proportion of babies were extubated at day 7 of life [5/8 (62.5%) in the very low-dose dexamethasone group vs. 2/6 (33.3%) in the placebo group] and duration of invasive ventilation was lower (a median of 23 days for the very low-dose dexamethasone group vs. a median of 31 days for the placebo group) in the very low-dose dexamethasone group. This is supported by a trend for an increased requirement for open-label rescue steroids in control group babies (41.7% in the very low-dose dexamethasone group vs. 80% in the placebo group). Given the limited sample size, only descriptive statistics can be given; firm conclusions cannot be drawn. Limitations Small sample size and high rates of open-label treatment use. Conclusions It is not feasible to conduct the required pragmatic trial of clinical effectiveness. Future work Assessment of very low-dose dexamethasone in this patient group requires careful consideration. Study registration Clinical Controlled Trials ISRCTN81191607. Funding This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. The report will be published in full in Efficacy and Mechanism; Vol. 6, No. 8. See the NIHR Journals Library website for further project information. The funding for the cytokine analysis is provided by the Children’s Charity Cerebra and is being carried out beyond the lifespan of the NIHR funding.

show abstract

Effects of Hochuekkito, a traditional Japanese medicine (Kampo), on reproduction of aging female mice

Sato

Kawagoe

et al. 2021

Reprod Medicine & Biology

View full text Add to dashboard Cite

Purpose To determine the potentials of Hochuekkito (HET) treatment for aging infertility. Methods Mice at 36 weeks of age were fed without (control, n = 40) or with low (100 mg/kg/day, n = 24) and high (1000 mg/kg/day, n = 38) doses of HET for 12 weeks. Aging animals at 48 weeks of age were used for in vitro fertilization‐embryo transfer (IVF‐ET), and their ovaries were subjected to histological and quantitative inflammation analyses. Results HET administration decreased transcript levels of ovarian inflammatory markers, interleukin 6 (IL‐6), IL‐1β, tumor necrosis factor (TNF)‐α, and interferon‐gamma (IFN‐γ) but suppressed ovulation rates and the number of ovulated oocytes in aging mice. Furthermore, HET treatment decreased the rates of oocytes maturation and fertilization and the cumulus‐cell expression of TNF‐α‐induced protein 6 and epidermal growth factor receptor. After IVF‐ET, no improvement of declined live offspring rate by aging was achieved by HET administration, although there were no adverse effects on embryo development and implantation as well as gross morphology and bodyweight of pups. Conclusion Present study indicated HET treatment interfered with ovulation and fertilization in aging mice without affecting ovarian follicle development. No improvement on the age‐associated decline of live offspring rate and follicle development was achieved after HET treatment.

show abstract

Follicular-phase ovarian follicular fluid and plasma cytokine profiling of natural cycle in vitro fertilization patients

Cited by 30 publications

References 77 publications

Is there an immune modulating role for follicular fluid in endometriosis? A narrative review

Is there an immune modulating role for follicular fluid in endometriosis? A narrative review

Very low-dose dexamethasone to facilitate extubation of preterm babies at risk of bronchopulmonary dysplasia: the MINIDEX feasibility RCT

Effects of Hochuekkito, a traditional Japanese medicine (Kampo), on reproduction of aging female mice

Contact Info

Product

Resources

About